In vitro activity of triclosan ( TCN ) and thiolactomycin ( TLM ) against multi-drug-resistant ( MDR ) strains of mycobacterium tuberculosis ( M. tb ) Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004
Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains Source: Eur Respir J 2015; 45: 285-287 Year: 2015
Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains Source: Eur Respir J 2015; 45: 287-289 Year: 2015
Minimal inhibitory concentrations (MICs) of mefloquine: in vitro activity against MDR- and nonMDR-Tb strains Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Comparative analysis between multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) in HIV(+) patients Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009
Treatment possibilities of multi-drug resistant (MDR) tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 525s Year: 2003
Relationship between rpoB mutations and minimum inhibitory concentrations of rifampicin in multi drug resistant strains of mycobacterium tuberculosis Source: Annual Congress 2011 - Tuberculosis: from bench to bedside Year: 2011
Treatment of multidrug resistant pulmonary tuberculosis (MDR-TB) with different pattern of resistance Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004
Primary multidrug resistance (PMDR) of mycobacterium tuberculosis (MBT) to antimycobacterial drugs (AMBTD) in the patients with destructive TB. Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Second and third line anti-tuberculosis drug's side effects during the treatment of patients with multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 555s Year: 2003
In vitro and in vivo activity of thiourea (ISO), a mycolic acid inhibitor, against multi drug resistant (MDR) strains of Mycobacterium tuberculosis (M. tb )Source: Eur Respir J 2005; 26: Suppl. 49, 700s Year: 2005
Minimum inhibitory concentrations (MIC) determination of TB drugs and broad-spectrum antibiotics in M.tuberculosis with M/X/TDR Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Treatment results of multidrug resistant pulmonary tuberculosis (MDR-TB) Source: Eur Respir J 2005; 26: Suppl. 49, 199s Year: 2005
Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005
In vitro and vivo study of isoxyl, a mycolic acid inhibitor for intermittent chemotherapy of multi drug resistant (MDR) strains of mycobacterium tuberculosis (M.tb)Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006
Rapid molecular detection of rifampicin and isoniazid resistance and identification of mutations in resistant genes of multi-drug resistant tuberculosis (MDR-TB) patients Source: Annual Congress 2011 - Novel strategies for the diagnosis of tuberculosis Year: 2011
Drug resistance patterns in patients with multi-drug resistant tuberculosis (MDR – TB) Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: diagnostic tools Year: 2012
Amikacin (AMK) minimum inhibitory concentrations (MICs) and mutational resistance in patients with treatment-refractory nontuberculous mycobacteria (NTM) lung disease (LD) treated with liposomal amikacin for inhalation (LAI) Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook Year: 2015
Phenotypic resistance of M. tuberculosis to bedaquilin (BDQ) and linezolid (LZD) Source: Virtual Congress 2021 – Challenges and advances in the diagnosis and clinical management of tuberculosis Year: 2021